[NCI CIRB] MA.39 - TAILOR RT: A RANDOMIZED TRIAL OF REGIONAL RADIOTHERAPY IN BIOMARKER LOW RISK NODE POSITIVE BREAST CANCER
The purpose of this study is to compare any good and bad effects of not giving regional radiotherapy to using regional radiotherapy. This study will help researchers learn if not giving regional radiotherapy is just as good as using regional radiotherapy.
Patient’s age must be ≥ 40 years.
Patient’s life expectancy is ≥ 10 years.
Patients must have newly diagnosed histologically proven invasive carcinoma of the breast with no evidence of metastases.
Patients must have been treated by BCS or mastectomy.
Patients treated by BCS or mastectomy and axillary dissection must have 1-3 positive axillary nodes (macrometastases, > 2 mm)*.
Patients treated by BCS and SLNB alone must have only 1-2 positive axillary nodes (macrometastases, > 2 mm)*.
Patients treated by mastectomy and SLNB alone must have only 1 positive axillary node (macrometastases, > 2 mm)*.
Patients must be ER ≥ 1% and HER2 negative on local testing
Patients must have an Oncotype DX recurrence score <18
Patients must have had endocrine therapy initiated or planned for ≥ 5 years. Endocrine therapy can be given concurrently or following RT.
Patients may or may not have had adjuvant chemotherapy.
40 - 99
Healthy Volunteers Needed
Duration of Participation
Treatment will last for up to 6 weeks. Once finished with radiotherapy, patients will be followed until death or study closure.
Knight Cancer Institute Clinical Trials